# Title

 Commercial Practices. PART 1702â€”PETITIONS FOR EXEMPTIONS FROM POISON PREVENTION PACKAGING ACT REQUIREMENTS; PETITION PROCEDURES AND REQUIREMENTS


# ID

 CFR-2018-title16-vol2.Pt. 1702


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                    |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['at least', 'minimum', 'prior to', 'within']                                                                                                                                                                             |
| Duration    | ['7 day']                                                                                                                                                                                                                 |
| Condition   | ['subject to', 'provided that', 'unless', 'as soon as', 'if', 'where', 'when']                                                                                                                                            |
| Entities    | ['Median', 'Washington, D.C', 'Effect', 'Such', 'Human', 'East', 'English', 'Good', 'Failure', 'Bethesda, MD', 'Product', 'Certain', 'Purpose', 'Trade', 'Household', 'New Drug', 'New Drug Application', 'Experimental'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                           |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------|
| at least      | of the petitioner, and (4) Be accompanied by at least  five (5) copies of the petition.                                           |
| within        | not satisfactorily explain the absence of the information within a reasonable time, the petition shall be closed                  |
| minimum       | The  minimum toxicological evaluation necessary for a particular household substance                                              |
| minimum       | Section 1702.9(a) lists  minimum acute animal toxicity data which shall be submitted,                                             |
| minimum       | pharmacological and toxicological practice which includes, as a minimum , complete descriptions of protocols used in experimental |
| at least      | Acute toxicity studies submitted with petitions should have at least  a seven day observation period of test animals.             |
| prior to      | test substance, provided that such animals are examined prior to  the onset of autolysis.                                         |


## Duration

| Duration   | Context                                                                                                                  |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------|
| 7 day      | (6) Acute toxicity studies submitted with petitions should have at least a seven day observation period of test animals. |


## Condition

| Condition     | Context                                                                                                                                         |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------------------|
| when          | There may be occasions, however,  when the Commission determines that a particular substance should                                             |
| when          | and explain that the petition may be resubmitted when  the deficiency is corrected.                                                             |
| if            | information is not submitted to the Commission, or if the petitioner does not satisfactorily explain the absence                                |
| if            | information is not submitted to the Commission, or if the petitioner does not satisfactorily explain the absence                                |
| if            | (a) If the just if ication is based on a lack of need                                                                                           |
| if            | practicable, or appropriate for the substance, the just if ication shall explain why.                                                           |
| if            | is incompatible with the particular substance, the just if ication shall explain why.                                                           |
| if            | similar data in adults shall also be submitted if  available.                                                                                   |
| where         | pharmacological, and toxicological literature, and (d) For drugs, where the human experience data submitted is based on                         |
| subject to    | expected, in normal use, to contact man are subject to less extensive studies than those substances, such as                                    |
| if            | acute animal toxicity data which shall be submitted, if reasonably available, for all petitions; &#167;&#8201;1702.9(b) lists those             |
| if            | acute animal toxicity data which shall be submitted, if reasonably available, for all petitions; &#167;&#8201;1702.9(b) lists those             |
| if            | acute animal toxicity data which shall be submitted, if reasonably available, for all petitions; &#167;&#8201;1702.9(b) lists those             |
| if            | the original study (e.g., results of histopathological examinations, if  performed).                                                            |
| subject to    | administration should be followed for studies involving substances subject to regulations promulgated under the Poison Prevention Packaging Act |
| where         | toxic potential of a substance, LD50 determinations should, where an LD50 value may be calculated, include: (i)                                 |
| provided that | in the literature are acceptable to the Commission provided that  a copy of the published work is submitted.                                    |
| as soon as    | Succumbing animals should be necropsied  as soon as practicable following death, while surviving animals should be                              |
| provided that | performed upon animals succumbing to the test substance, provided that such animals are examined prior to the onset                             |
| when          | Results of microscopic examinations,  when indicated by the nature or results of an                                                             |
| where         | (a) of this section submit the following data, where reasonably available: (i) Summary laboratory reports of data                               |
| where         | (a) of this section submit the following data, where reasonably available: (i) Summary laboratory reports of data                               |
| where         | In certain cases  where the experimental data specified by &#167;&#8201;1702.9 (a) and                                                          |
| where         | In certain cases  where the experimental data specified by &#167;&#8201;1702.9 (a) and                                                          |
| where         | may be available to a petitioner and should, where  reasonably available, be submitted.                                                         |
| where         | data obtained in subacute and chronic animal studies where such data pertain to the absorption, distribution, metabolism,                       |
| if            | size for the product should also be indicated, if  known.                                                                                       |
| where         | shall submit adequate evidence to support the allegation. where                                                                                 |
| if            | NDA in order to allow additional package choice. if                                                                                             |
| if            | based upon the fact that the shelf l if e of the product limits package choice, the                                                             |
| where         | Food and Drug Administration's Adverse Reaction Reporting Program. where                                                                        |
| subject to    | Therefore, substances  subject to special packaging standards shall be considered in violation                                                  |
| unless        | shall be considered in violation of the law unless packaged in special packaging during the Commission's consideration                          |


## Entities

| Entities             | Context                                                                                                                 |
|:---------------------|:------------------------------------------------------------------------------------------------------------------------|
| Purpose              | Purpose  and policy.                                                                                                    |
| Washington, D.C      | Office of the Secretary, Consumer Product Safety Commission, Washington, D.C . 20207, or delivered to the Office of     |
| East                 | of the Secretary, Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814, (2) Be written        |
| Bethesda, MD         | Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814, (2) Be written in the English language, |
| English              | Bethesda, MD 20814, (2) Be written in the English language, (3) Contain the name and address of                         |
| New Drug             | the FDA for an Investigational Exemption for a New Drug  (IND) or a                                                     |
| New Drug Application | Exemption for a New Drug (IND) or a New Drug Application  (NDA).                                                        |
| Failure              | Failure  to supply adverse information.                                                                                 |
| Failure              | Failure to obtain and provide the Commission with all                                                                   |
| Trade                | Trade  secrets and other confidential information.                                                                      |
| Such                 | Such information in children is of particular importance in                                                             |
| New Drug             | be compiled for an Investigational Exemption for a New Drug  (IND), 21 CFR part 312, or a                               |
| New Drug Application | Drug (IND), 21 CFR part 312, or a New Drug Application (NDA), 21 CFR part 314, a summary of                             |
| Experimental         | Experimental data are generated in both animals and humans                                                              |
| Certain              | Certain toxicological effects cannot generally be evaluated in human                                                    |
| Household            | Household substances which are not expected, in normal use,                                                             |
| Median               | petition shall include all reasonably available reports of Median Lethal Dosage (LD50) studies and shall include all    |
| Good                 | Good pharmacological practice provides that test animals are observed                                                   |
| Human                | Human  experimental data involving the testing of human subjects.                                                       |
| Product              | Product  specifications.                                                                                                |
| Effect               | Effect  of filing petition.                                                                                             |


